CYP2D6

                                                                                                 (Cytochrome P450 2D6)

  • Alias                                 (According to NCBI)

 

  • CPD6
  • CYP2D
  • CYP2D@
  • CYP2DL1
  • HGNC:2629
  • P450-DB1
  • P450C2D 
  • cytochrome P450, family 2, subfamily D, polypeptide 6
  • cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6
  • cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1
  • debrisoquine 4-hydroxylase
  • flavoprotein-linked monooxygenase
  • microsomal monooxygenase
  • xenobiotic monooxygenase
  • Cytochrome P450 2D6 (EC 1.14.14.1) (CYPIID6) (P450-DB1) (Debrisoquine 4-hydroxylase)
  • This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 20% of commonly prescribed drugs. Its substrates include debrisoquine, an adrenergic-blocking drug; sparteine and propafenone, both anti-arrythmic drugs; and amitryptiline, an anti-depressant. The gene is highly polymorphic in the population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates.

  • Location: 22q13.1
  • Orientation: Minus strand
  • Size: 14,724 bases
  • 9 Exons
  • DNA Sequence: NG_003180

                 

  • CGH (22q13.1):  Losses (%)  -1.1 Gain (%)  15.1 

  • Mutations and SNPs (According to HGMD and SNP)
  • m-RNA                       (According to NCBI and CGAP)

 

  • Size:497 amino acids; 55801 Da
  • Sub cellular location: Membrane-bound. Endoplasmic reticulum
  • Catalytic activity: RH + reduced flavoprotein + O(2) = ROH + oxidized flavoprotein + H(2)O
  • Protein domains:

              

  • Protein sequence: P10635
  • Homologous sequences:
  • 2D PAGE:
  • 3D Structure: 2F9Q
  • PTM: CYP2D6
  • Pathways and interactions (According to BioCarta, DIP)
  • Clinical                            (According to OMIM, PubMed)